Cargando…
Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
Insulin degludec/insulin aspart (IDegAsp) is the first soluble co-formulation which combines two insulin analogues, and provides effective basal and prandial glycemic coverage. It has been assessed as basal insulin in type 2 diabetes mellitus (T2DM), and as part of basal-bolus regime in both type 1...
Autor principal: | Kalra, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065296/ https://www.ncbi.nlm.nih.gov/pubmed/24828136 http://dx.doi.org/10.1007/s13300-014-0067-x |
Ejemplares similares
-
Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016) -
Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
por: Kalra, Sanjay, et al.
Publicado: (2016) -
Insulin degludec aspart: One-year real world experience
por: Kalra, Sanjay, et al.
Publicado: (2016) -
Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011) -
Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
por: Havelund, Svend, et al.
Publicado: (2015)